ERASCA INC (ERAS) Stock Price, Quote, News and Overview
NASDAQ:ERAS - Nasdaq - US29479A1088 - Common Stock - Currency: USD
ERAS Quote, Performance and Key Statistics
1.41
-0.05 (-3.42%)
The current stock price of ERAS is 1.41 USD. In the past month the price decreased by -29.15%. In the past year, price decreased by -39.22%.
ERAS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ERAS
Company Profile
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is headquartered in San Diego, California and currently employs 126 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Company Info
ERASCA INC
10835 Road To The Cure, Suite 140
San Diego CALIFORNIA US
Employees: 126
Company Website: https://www.erasca.com/
Investor Relations: https://investors.erasca.com/
Phone: 18584656511
ERASCA INC / ERAS FAQ
What is the stock price of ERASCA INC today?
The current stock price of ERAS is 1.41 USD. The price decreased by -3.42% in the last trading session.
What is the ticker symbol for ERASCA INC stock?
The exchange symbol of ERASCA INC is ERAS and it is listed on the Nasdaq exchange.
On which exchange is ERAS stock listed?
ERAS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ERASCA INC stock?
14 analysts have analysed ERAS and the average price target is 5.1 USD. This implies a price increase of 261.7% is expected in the next year compared to the current price of 1.41. Check the ERASCA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ERASCA INC worth?
ERASCA INC (ERAS) has a market capitalization of 398.65M USD. This makes ERAS a Small Cap stock.
How many employees does ERASCA INC have?
ERASCA INC (ERAS) currently has 126 employees.
What are the support and resistance levels for ERASCA INC (ERAS) stock?
ERASCA INC (ERAS) has a resistance level at 2.15. Check the full technical report for a detailed analysis of ERAS support and resistance levels.
Should I buy ERASCA INC (ERAS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ERAS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ERAS, evaluating the profitability, health, valuation and growth aspects
- ERASCA INC (ERAS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ERASCA INC (ERAS) Sales and EPS estimates to see what analysts future expectations are.
- ERASCA INC (ERAS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ERASCA INC (ERAS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ERASCA INC (ERAS) Stock Chart to make your own analysis
- ERASCA INC (ERAS) Latest news and press-releases to stay up to date.
Does ERASCA INC (ERAS) stock pay dividends?
ERAS does not pay a dividend.
What is the Price/Earnings (PE) ratio of ERASCA INC (ERAS)?
ERASCA INC (ERAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).
What is the Short Interest ratio of ERASCA INC (ERAS) stock?
The outstanding short interest for ERASCA INC (ERAS) is 14.79% of its float. Check the ownership tab for more information on the ERAS short interest.
ERAS Technical Analysis
ERAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERAS. ERAS has a great financial health rating, but its profitability evaluates not so good.
ERAS Financial Highlights
Over the last trailing twelve months ERAS reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 50.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.09% | ||
| ROE | -35.36% | ||
| Debt/Equity | 0 |
ERAS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ERAS. The Buy consensus is the average rating of analysts ratings from 14 analysts.